Previous 10 | Next 10 |
AnPac Bio-Medical Science (ANPC) +75% after update on cancer detection system CDAPS.Second Sight Medical Products (EYES) +67%.GT Biopharma (GTBP) +45%.Auris Medical Holding Ltd. (EARS) +24%.Taoping Inc. (TAOP) +10% on launching Blockchain Business Division.AirNet Technology (ANTE) +...
Aytu BioScience (AYTU) shares up nearly 15% in after market trading after announcing that data from a first in-human, open label, clinical trial in SARS-CoV-2 patients has been released in MedRxiv, an online archive for health science pre-print manuscripts that are not yet...
Data indicate endotracheal UVA light catheter therapy reduces SARS-CoV-2 viral load and improves clinical outcomes in mechanically ventilated SARS-CoV-2 patients ENGLEWOOD, CO / ACCESSWIRE / March 8, 2021 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused...
Merger activity increased last week. Six multi-billion-dollar deals announced. SPAC frenzy hits a new record. For further details see: Merger Arbitrage Mondays: SPAC IPOs Set A New Record
ENGLEWOOD, CO / ACCESSWIRE / February 24, 2021 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that Josh Disbrow, Chairman and Chief Executive Officer will present at t...
Merger activity decreased last week with four new deals announced. The acquisition of Enable Midstream Partners by Energy Transfer. The acquisition of Tribune Publishing Company by Alden Golden Capital. For further details see: Merger Arbitrage Mondays - Consolidati...
Merger activity increased last week with five new deals announced. The acquisition of Glu Mobile by Electronic Arts. MKS Instruments and II-VI Incorporated bid for Coherent. For further details see: Merger Arbitrage Mondays - Bidding War For Coherent Continues
Aytu BioScience, Inc. (AYTU) Q2 2021 Earnings Conference Call February 11, 2021, 16:30 ET Company Participants Joshua Disbrow - Chairman & CEO David Green - CFO, Secretary & Treasurer Conference Call Participants Vernon Bernardino - H.C. Wainwright & Co. Presentation Operator Good...
Aytu BioScience (AYTU): FQ2 GAAP EPS of -$0.72 misses by $0.28.Revenue of $15.15M (+376.4% Y/Y) beats by $2.9M.Ended the quarter with $62.3M in cash, equivalents and restricted cash.Announced definitive merger agreement with Neos Therapeutics, creating a combined $100M revenue specialty pharm...
Announced definitive merger agreement with Neos Therapeutics, creating a combined $100 million revenue specialty pharmaceutical company Q2 Consumer Health division revenue reaches an all-time high of $7.9 million Q2 Rx division revenue up 24% sequentially Ended the quarter wit...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...